There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for PTIX is 5.82M and currently, short sellers hold a 1.69% ratio of that float. The average trading volume of PTIX on December 18, 2024 was 174.08K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PTIX) stock’s latest price update
Protagenic Therapeutics Inc (NASDAQ: PTIX)’s stock price has increased by 16.07 compared to its previous closing price of 0.56. However, the company has seen a 24.95% increase in its stock price over the last five trading sessions. accesswire.com reported 2024-11-05 that NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) (“Protagenic Therapeutics” or the “Company”), a leader in biopharmaceutical innovation, announced today that on November 4, 2024 it closed its previously announced private placement pursuant to a purchase agreement (the “Purchase Agreement”) for the purchase and sale of an aggregate of 1,948,295 shares of common stock, series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date, and series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. The purchase price of each share of common stock and associated common stock purchase warrants was $0.64 ($0.89 in the case of insiders).
PTIX’s Market Performance
Protagenic Therapeutics Inc (PTIX) has experienced a 24.95% rise in stock performance for the past week, with a 12.09% rise in the past month, and a 9.43% rise in the past quarter. The volatility ratio for the week is 8.29%, and the volatility levels for the past 30 days are at 14.59% for PTIX. The simple moving average for the past 20 days is 14.16% for PTIX’s stock, with a -29.45% simple moving average for the past 200 days.
PTIX Trading at 8.59% from the 50-Day Moving Average
After a stumble in the market that brought PTIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.24% of loss for the given period.
Volatility was left at 14.59%, however, over the last 30 days, the volatility rate increased by 8.29%, as shares surge +13.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.78% upper at present.
During the last 5 trading sessions, PTIX rose by +26.87%, which changed the moving average for the period of 200-days by -34.01% in comparison to the 20-day moving average, which settled at $0.5699. In addition, Protagenic Therapeutics Inc saw -34.34% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PTIX
Current profitability levels for the company are sitting at:
- -185.94 for the present operating margin
- -0.83 for the gross margin
The net margin for Protagenic Therapeutics Inc stands at -199.27. The total capital return value is set at -7.33. Equity return is now at value -231.87, with -162.74 for asset returns.
Currently, EBITDA for the company is -4.5 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 124.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.80.
Conclusion
In conclusion, Protagenic Therapeutics Inc (PTIX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
